Long-Term Persistence with Injectable Therapy in Relapsing-Remitting Multiple Sclerosis: An 18-Year Observational Cohort Study

Disease modifying therapies (DMTs) reduce the frequency of relapses and accumulation of disability in multiple sclerosis (MS). Long-term persistence with treatment is important to optimize treatment benefit. This long-term, cohort study was conducted at the Calgary MS Clinic. All consenting adults w...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	PloS one Ročník 10; číslo 4; s. e0123824
Hlavní autoři:	Zhornitsky, Simon, Greenfield, Jamie, Koch, Marcus W., Patten, Scott B., Harris, Colleen, Wall, Winona, Alikhani, Katayoun, Burton, Jodie, Busche, Kevin, Costello, Fiona, Davenport, Jeptha W., Jarvis, Scott E., Lavarato, Dina, Parpal, Helene, Patry, David G., Yeung, Michael, Metz, Luanne M.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Public Library of Science 13.04.2015 Public Library of Science (PLoS)
Témata:	Adult Adults Analysis Autoimmune diseases Biological response modifiers Cohort analysis Cohort Studies Copolymer 1 Diabetes Drug dosages Female Footprints Glatiramer Acetate - administration & dosage Hepatitis Humans Injections, Subcutaneous Interferon Interferon beta-1a - administration & dosage Interferon beta-1b - administration & dosage Male Medicine Middle Aged Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - drug therapy Neurosciences Nurses Observational studies Patients Population Population studies Pregnancy Rank tests Regression analysis Regression models Switches β-Interferon Canada United States > US Calgary Alberta Canada
ISSN:	1932-6203, 1932-6203
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Disease modifying therapies (DMTs) reduce the frequency of relapses and accumulation of disability in multiple sclerosis (MS). Long-term persistence with treatment is important to optimize treatment benefit. This long-term, cohort study was conducted at the Calgary MS Clinic. All consenting adults with relapsing-remitting MS who started either glatiramer acetate (GA) or interferon-β 1a/1b (IFN-β) between January 1st, 1996 and July 1st, 2011 were included. Follow-up continued to February 1st, 2014. Time-to-discontinuation of the initial and subsequently-prescribed DMTs (switches) was analysed using Kaplan-Meier survival analyses. Group differences were compared using log-rank tests and multivariable Cox regression models. Analysis included 1471 participants; 906 were initially prescribed GA and 565 were initially prescribed IFN-β. Follow-up information was available for 87%; 29 (2%) were lost to follow-up and 160 (11%) moved from Southern Alberta while still using DMT. Median time-to-discontinuation of all injectable DMTs was 11.1 years. Participants with greater disability at treatment initiation, those who started treatment before age 30, and those who started between 2006 and 2011 were more likely to discontinue use of all injectable DMTs. Median time-to-discontinuation of the initial DMT was 8.6 years. Those initially prescribed GA remained on treatment longer. Of 610 participants who discontinued injectable DMT, 331 (54%) started an oral DMT, or a second-line DMT, or resumed injectable DMT after 90 days. Persistence with injectable DMTs was high in this long-term population-based study. Most participants who discontinued injectable DMT did not remain untreated. Further research is required to understand treatment outcomes and outcomes after stopping DMT.
AbstractList	Disease modifying therapies (DMTs) reduce the frequency of relapses and accumulation of disability in multiple sclerosis (MS). Long-term persistence with treatment is important to optimize treatment benefit. This long-term, cohort study was conducted at the Calgary MS Clinic. All consenting adults with relapsing-remitting MS who started either glatiramer acetate (GA) or interferon-β 1a/1b (IFN-β) between January 1st, 1996 and July 1st, 2011 were included. Follow-up continued to February 1st, 2014. Time-to-discontinuation of the initial and subsequently-prescribed DMTs (switches) was analysed using Kaplan-Meier survival analyses. Group differences were compared using log-rank tests and multivariable Cox regression models. Analysis included 1471 participants; 906 were initially prescribed GA and 565 were initially prescribed IFN-β. Follow-up information was available for 87%; 29 (2%) were lost to follow-up and 160 (11%) moved from Southern Alberta while still using DMT. Median time-to-discontinuation of all injectable DMTs was 11.1 years. Participants with greater disability at treatment initiation, those who started treatment before age 30, and those who started between 2006 and 2011 were more likely to discontinue use of all injectable DMTs. Median time-to-discontinuation of the initial DMT was 8.6 years. Those initially prescribed GA remained on treatment longer. Of 610 participants who discontinued injectable DMT, 331 (54%) started an oral DMT, or a second-line DMT, or resumed injectable DMT after 90 days. Persistence with injectable DMTs was high in this long-term population-based study. Most participants who discontinued injectable DMT did not remain untreated. Further research is required to understand treatment outcomes and outcomes after stopping DMT. Disease modifying therapies (DMTs) reduce the frequency of relapses and accumulation of disability in multiple sclerosis (MS). Long-term persistence with treatment is important to optimize treatment benefit. This long-term, cohort study was conducted at the Calgary MS Clinic. All consenting adults with relapsing-remitting MS who started either glatiramer acetate (GA) or interferon-[beta] 1a/1b (IFN-[beta]) between January 1.sup.st, 1996 and July 1.sup.st, 2011 were included. Follow-up continued to February 1.sup.st, 2014. Time-to-discontinuation of the initial and subsequently-prescribed DMTs (switches) was analysed using Kaplan-Meier survival analyses. Group differences were compared using log-rank tests and multivariable Cox regression models. Analysis included 1471 participants; 906 were initially prescribed GA and 565 were initially prescribed IFN-[beta]. Follow-up information was available for 87%; 29 (2%) were lost to follow-up and 160 (11%) moved from Southern Alberta while still using DMT. Median time-to-discontinuation of all injectable DMTs was 11.1 years. Participants with greater disability at treatment initiation, those who started treatment before age 30, and those who started between 2006 and 2011 were more likely to discontinue use of all injectable DMTs. Median time-to-discontinuation of the initial DMT was 8.6 years. Those initially prescribed GA remained on treatment longer. Of 610 participants who discontinued injectable DMT, 331 (54%) started an oral DMT, or a second-line DMT, or resumed injectable DMT after 90 days. Persistence with injectable DMTs was high in this long-term population-based study. Most participants who discontinued injectable DMT did not remain untreated. Further research is required to understand treatment outcomes and outcomes after stopping DMT. Disease modifying therapies (DMTs) reduce the frequency of relapses and accumulation of disability in multiple sclerosis (MS). Long-term persistence with treatment is important to optimize treatment benefit. This long-term, cohort study was conducted at the Calgary MS Clinic. All consenting adults with relapsing-remitting MS who started either glatiramer acetate (GA) or interferon-β 1a/1b (IFN-β) between January 1st, 1996 and July 1st, 2011 were included. Follow-up continued to February 1st, 2014. Time-to-discontinuation of the initial and subsequently-prescribed DMTs (switches) was analysed using Kaplan-Meier survival analyses. Group differences were compared using log-rank tests and multivariable Cox regression models. Analysis included 1471 participants; 906 were initially prescribed GA and 565 were initially prescribed IFN-β. Follow-up information was available for 87%; 29 (2%) were lost to follow-up and 160 (11%) moved from Southern Alberta while still using DMT. Median time-to-discontinuation of all injectable DMTs was 11.1 years. Participants with greater disability at treatment initiation, those who started treatment before age 30, and those who started between 2006 and 2011 were more likely to discontinue use of all injectable DMTs. Median time-to-discontinuation of the initial DMT was 8.6 years. Those initially prescribed GA remained on treatment longer. Of 610 participants who discontinued injectable DMT, 331 (54%) started an oral DMT, or a second-line DMT, or resumed injectable DMT after 90 days. Persistence with injectable DMTs was high in this long-term population-based study. Most participants who discontinued injectable DMT did not remain untreated. Further research is required to understand treatment outcomes and outcomes after stopping DMT.Disease modifying therapies (DMTs) reduce the frequency of relapses and accumulation of disability in multiple sclerosis (MS). Long-term persistence with treatment is important to optimize treatment benefit. This long-term, cohort study was conducted at the Calgary MS Clinic. All consenting adults with relapsing-remitting MS who started either glatiramer acetate (GA) or interferon-β 1a/1b (IFN-β) between January 1st, 1996 and July 1st, 2011 were included. Follow-up continued to February 1st, 2014. Time-to-discontinuation of the initial and subsequently-prescribed DMTs (switches) was analysed using Kaplan-Meier survival analyses. Group differences were compared using log-rank tests and multivariable Cox regression models. Analysis included 1471 participants; 906 were initially prescribed GA and 565 were initially prescribed IFN-β. Follow-up information was available for 87%; 29 (2%) were lost to follow-up and 160 (11%) moved from Southern Alberta while still using DMT. Median time-to-discontinuation of all injectable DMTs was 11.1 years. Participants with greater disability at treatment initiation, those who started treatment before age 30, and those who started between 2006 and 2011 were more likely to discontinue use of all injectable DMTs. Median time-to-discontinuation of the initial DMT was 8.6 years. Those initially prescribed GA remained on treatment longer. Of 610 participants who discontinued injectable DMT, 331 (54%) started an oral DMT, or a second-line DMT, or resumed injectable DMT after 90 days. Persistence with injectable DMTs was high in this long-term population-based study. Most participants who discontinued injectable DMT did not remain untreated. Further research is required to understand treatment outcomes and outcomes after stopping DMT.
Audience	Academic
Author	Davenport, Jeptha W. Alikhani, Katayoun Greenfield, Jamie Lavarato, Dina Wall, Winona Patry, David G. Zhornitsky, Simon Burton, Jodie Jarvis, Scott E. Metz, Luanne M. Patten, Scott B. Busche, Kevin Parpal, Helene Costello, Fiona Yeung, Michael Harris, Colleen Koch, Marcus W.
AuthorAffiliation	1 Department of Clinical Neurosciences, Faculty of Medicine, University of Calgary; Calgary, Canada 2 Department of Psychiatry, Faculty of Medicine, University of Calgary, Calgary, Canada 3 Hotchkiss Brain Institute, Faculty of Medicine, University of Calgary, Calgary, Canada Friedrich-Alexander University Erlangen, GERMANY
AuthorAffiliation_xml	– name: 1 Department of Clinical Neurosciences, Faculty of Medicine, University of Calgary; Calgary, Canada – name: Friedrich-Alexander University Erlangen, GERMANY – name: 2 Department of Psychiatry, Faculty of Medicine, University of Calgary, Calgary, Canada – name: 3 Hotchkiss Brain Institute, Faculty of Medicine, University of Calgary, Calgary, Canada
Author_xml	– sequence: 1 givenname: Simon surname: Zhornitsky fullname: Zhornitsky, Simon – sequence: 2 givenname: Jamie surname: Greenfield fullname: Greenfield, Jamie – sequence: 3 givenname: Marcus W. surname: Koch fullname: Koch, Marcus W. – sequence: 4 givenname: Scott B. surname: Patten fullname: Patten, Scott B. – sequence: 5 givenname: Colleen surname: Harris fullname: Harris, Colleen – sequence: 6 givenname: Winona surname: Wall fullname: Wall, Winona – sequence: 7 givenname: Katayoun surname: Alikhani fullname: Alikhani, Katayoun – sequence: 8 givenname: Jodie surname: Burton fullname: Burton, Jodie – sequence: 9 givenname: Kevin surname: Busche fullname: Busche, Kevin – sequence: 10 givenname: Fiona surname: Costello fullname: Costello, Fiona – sequence: 11 givenname: Jeptha W. surname: Davenport fullname: Davenport, Jeptha W. – sequence: 12 givenname: Scott E. surname: Jarvis fullname: Jarvis, Scott E. – sequence: 13 givenname: Dina surname: Lavarato fullname: Lavarato, Dina – sequence: 14 givenname: Helene surname: Parpal fullname: Parpal, Helene – sequence: 15 givenname: David G. surname: Patry fullname: Patry, David G. – sequence: 16 givenname: Michael surname: Yeung fullname: Yeung, Michael – sequence: 17 givenname: Luanne M. surname: Metz fullname: Metz, Luanne M.
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/25867095$$D View this record in MEDLINE/PubMed
BookMark	eNqNk99v0zAQxyM0xH7Af4Ag0iQEDy2OkzjxHpCmiR-Vioa2gcSTdXUurSs3LrYz2At_O9e1Q-00IZSHWJfP9-u7y91hste5DpPkecaGWV5lb-eu9x3Y4ZLCQ5bxvObFo-QgkzkfCM7yva3zfnIYwpyxMq-FeJLs87IWFZPlQfJ77Lrp4Ar9Iv2CPpgQsdOY_jRxlo66OeoIE4vp1Qw9LG9S06UXaGEZDKkucGFipFP6ubfRLIm71Ba9I5uT9LRLs3rwHcGn55OA_hqicZRweuZmzsf0MvbNzdPkcQs24LPN-yj5-uH91dmnwfj84-jsdDzQQvI4yEGIogHeVBPeMKhlK4AjlNBiUWAzaWUpJdQc2ETIRrNCt9CKCiuQNZaY50fJy7Xv0rqgNq0LKhNVnnHGK0HEaE00DuZq6c0C_I1yYNRtwPmpAh8N1afyttZ1WzHWlrLIQAKTKEuQomQVYFOS17vNbf1kgY3GLnqwO6a7XzozU1N3rYpclpQNGbzeGHj3o8cQ1cIEjdZCh65f551XlLgk9Pge-nB1G2oKVIDpWkf36pWpOi04MaKoV10aPkDR09Cf1jRnraH4juDNjoCYiL_iFPoQ1Ojy4v_Z82-77KstdoZg4yw4268mKOyCL7Y7_bfFdwNOwMka0DSWwWOrtIm3k0ilGasyplbbdNc0tdomtdkmEhf3xHf-_5T9AR4TJLM
CitedBy_id	crossref_primary_10_1007_s00415_019_09211_5 crossref_primary_10_1016_j_msard_2018_12_025 crossref_primary_10_1177_00185787241232615 crossref_primary_10_1080_03007995_2017_1380616 crossref_primary_10_1371_journal_pone_0238476 crossref_primary_10_1016_j_msard_2020_101929 crossref_primary_10_1186_s12913_020_05664_x crossref_primary_10_1186_s12883_017_0831_4 crossref_primary_10_1177_2055217317696114 crossref_primary_10_1155_2019_7151685 crossref_primary_10_1016_j_jocn_2017_02_004 crossref_primary_10_1111_ane_12705 crossref_primary_10_1016_j_msard_2020_102004 crossref_primary_10_1016_j_msard_2023_104909 crossref_primary_10_1007_s00415_019_09625_1 crossref_primary_10_1016_j_msard_2016_09_011 crossref_primary_10_1177_2055217316677868 crossref_primary_10_1186_s12883_022_02738_7
Cites_doi	10.1185/03007990903554257 10.1007/s12325-011-0074-5 10.1016/S0140-6736(98)03334-0 10.1111/cns.12235 10.1185/03007995.2011.598500 10.1212/WNL.45.7.1268 10.1185/03007990903421994 10.1111/j.1468-1331.2005.00936.x 10.1111/j.1600-0404.2009.01285.x 10.1017/S0317167100011823 10.1002/ana.20703 10.2500/aap.2009.30.3190 10.1016/j.clineuro.2012.02.043 10.2147/PPA.S8230 10.1186/1471-2377-14-11 10.2146/ajhp080711 10.1111/j.1365-2710.2011.01276.x 10.1212/WNL.43.4.655 10.1212/WNL.56.3.422 10.3111/13696998.2010.527588 10.1080/09540121.2010.543884 10.1007/s10865-010-9247-y 10.1002/ana.410390304 10.2147/PPA.S15702 10.1016/j.clinthera.2010.01.008 10.1038/nrneurol.2012.168 10.1191/1352458505ms1173oa 10.1371/journal.pone.0059694 10.1159/000111875 10.1186/1471-2377-11-122 10.3371/CSRP.6.2.3 10.1212/01.WNL.0000078885.05053.7D 10.1111/j.1365-2710.2008.00912.x 10.1016/j.clinthera.2006.09.021 10.1191/1352458505ms1131oa 10.1016/j.clinthera.2012.01.006
ContentType	Journal Article
Copyright	COPYRIGHT 2015 Public Library of Science 2015 Zhornitsky et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2015 Zhornitsky et al 2015 Zhornitsky et al
Copyright_xml	– notice: COPYRIGHT 2015 Public Library of Science – notice: 2015 Zhornitsky et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2015 Zhornitsky et al 2015 Zhornitsky et al
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA
DOI	10.1371/journal.pone.0123824
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Computer Science Collection Agricultural & Environmental Science Collection ProQuest Central Essentials - QC Biological Science Collection ProQuest Central ProQuest Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection ProQuest Biological Science Collection Agricultural Science Database ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	Agricultural Science Database MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: ProQuest Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Sciences (General) Medicine
DocumentTitleAlternate	Persistence with Treatment in Relapsing-Remitting Multiple Sclerosis
EISSN	1932-6203
ExternalDocumentID	1673120276 oai_doaj_org_article_3f8c8f700f5941a9a09e95a96507aed5 PMC4395027 3654879561 A422026483 25867095 10_1371_journal_pone_0123824
Genre	Journal Article Observational Study
GeographicLocations	Canada United States--US Calgary Alberta Canada
GeographicLocations_xml	– name: Calgary Alberta Canada – name: Canada – name: United States--US
GroupedDBID	--- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACCTH ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFFHD AFKRA AFPKN AFRAH AHMBA ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAIFH BAWUL BBNVY BBTPI BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM ALIPV CGR CUY CVF ECM EIF IPNFZ NPM RIG BBORY 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO ESTFP FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 PUEGO 5PM - 02 AAPBV ABPTK ADACO BBAFP KM
ID	FETCH-LOGICAL-c692t-3a664da2d7b2d0a89f6a2ea5afe44edbf9599a82a0b69dc04cfaf67e7a98e5e33
IEDL.DBID	FPL
ISICitedReferencesCount	23
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000352845100215&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1932-6203
IngestDate	Fri Nov 26 17:14:43 EST 2021 Fri Oct 03 12:51:27 EDT 2025 Tue Nov 04 01:51:02 EST 2025 Fri Sep 05 07:19:54 EDT 2025 Tue Oct 07 07:18:43 EDT 2025 Sat Nov 29 13:35:09 EST 2025 Sat Nov 29 10:23:50 EST 2025 Wed Nov 26 10:17:38 EST 2025 Wed Nov 26 09:56:25 EST 2025 Thu May 22 20:56:51 EDT 2025 Mon Jul 21 06:05:44 EDT 2025 Sat Nov 29 03:45:29 EST 2025 Tue Nov 18 21:37:27 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	4
Language	English
License	This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. Creative Commons Attribution License
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c692t-3a664da2d7b2d0a89f6a2ea5afe44edbf9599a82a0b69dc04cfaf67e7a98e5e33
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 Competing Interests: The authors have declared that no competing interests exist. Conceived and designed the experiments: LMM CH SBP. Performed the experiments: SZ JG MWK CH WW KA JB KB FC JWD SEJ DL HP DGP MY LMM. Analyzed the data: LMM SZ MWK JG WW. Wrote the paper: SZ JG LMM.
OpenAccessLink	http://dx.doi.org/10.1371/journal.pone.0123824
PMID	25867095
PQID	1673120276
PQPubID	1436336
ParticipantIDs	plos_journals_1673120276 doaj_primary_oai_doaj_org_article_3f8c8f700f5941a9a09e95a96507aed5 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4395027 proquest_miscellaneous_1673372029 proquest_journals_1673120276 gale_infotracmisc_A422026483 gale_infotracacademiconefile_A422026483 gale_incontextgauss_ISR_A422026483 gale_incontextgauss_IOV_A422026483 gale_healthsolutions_A422026483 pubmed_primary_25867095 crossref_citationtrail_10_1371_journal_pone_0123824 crossref_primary_10_1371_journal_pone_0123824
PublicationCentury	2000
PublicationDate	2015-04-13
PublicationDateYYYYMMDD	2015-04-13
PublicationDate_xml	– month: 04 year: 2015 text: 2015-04-13 day: 13
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States – name: San Francisco – name: San Francisco, CA USA
PublicationTitle	PloS one
PublicationTitleAlternate	PLoS One
PublicationYear	2015
Publisher	Public Library of Science Public Library of Science (PLoS)
Publisher_xml	– name: Public Library of Science – name: Public Library of Science (PLoS)
References	(ref2) 1993; 43 (ref5) 1998; 352 J Haas (ref26) 2005; 12 LB Jordan (ref36) 2012; 37 E Portaccio (ref22) 2008; 59 L Xie (ref32) 2011; 28 CH Polman (ref12) 2005; 58 JM Bruce (ref9) 2010; 33 A Wheeler (ref34) 2012; 6 M Agius (ref20) 2014; 20 MS Broder (ref35) 2009; 30 CE Cooke (ref30) 2010; 26 SU Iqbal (ref37) 2008; 33 T Juday (ref24) 2011; 23 PA Caetano (ref6) 2006; 28 A Cunningham (ref17) 2010; 121 HL Tremlett (ref28) 2003; 61 H Lassmann (ref1) 2012; 8 JM Margolis (ref21) 2011; 11 R Halpern (ref14) 2011; 5 F Patti (ref8) 2010; 4 NL Kleinman (ref11) 2010; 13 LD Jacobs (ref4) 1996; 39 E Buysman (ref31) 2011; 27 J Río (ref18) 2005; 11 KE O'Rourke (ref10) 2005; 11 A Helin-Salmivaara (ref23) 2010; 16 C Evans (ref16) 2012; 34 P Pechlivanoglou (ref33) 2010; 32 KP Johnson (ref3) 1995; 45 E Sabaté (ref7) 2003 S Mesaroš (ref29) 2012; 114 M Filippi (ref19) 2001; 56 DI Brixner (ref38) 2009; 66 VG Jokubaitis (ref15) 2013; 8 MW Reynolds (ref13) 2010; 26 M Oleen-Burkey (ref27) 2014; 14 J Wong (ref25) 2011; 38
References_xml	– volume: 26 start-page: 663 year: 2010 ident: ref13 article-title: Persistence and adherence to disease modifying drugs among patients with multiple sclerosis publication-title: Curr Med Res Opin doi: 10.1185/03007990903554257 – volume: 28 start-page: 1000 year: 2011 ident: ref32 article-title: A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens publication-title: Adv Ther doi: 10.1007/s12325-011-0074-5 – volume: 352 start-page: 1498 year: 1998 ident: ref5 article-title: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group publication-title: Lancet doi: 10.1016/S0140-6736(98)03334-0 – volume: 20 start-page: 446 year: 2014 ident: ref20 article-title: Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom publication-title: CNS Neurosci Ther doi: 10.1111/cns.12235 – volume: 27 start-page: 1709 year: 2011 ident: ref31 article-title: Adherence and persistence to a regimen of basal insulin in a pre-filled pen compared to vial/syringe in insulin-naïve patients with type 2 diabetes publication-title: Curr Med Res Opin doi: 10.1185/03007995.2011.598500 – volume: 45 start-page: 1268 year: 1995 ident: ref3 article-title: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group publication-title: Neurology doi: 10.1212/WNL.45.7.1268 – volume: 26 start-page: 231 year: 2010 ident: ref30 article-title: Persistence with injectable anti-diabetic agents in members with type 2 diabetes in a commercial managed care organization publication-title: Curr Med Res Opin doi: 10.1185/03007990903421994 – volume: 12 start-page: 425 year: 2005 ident: ref26 article-title: Twenty-four-month comparison of immunomodulatory treatments—a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone) publication-title: Eur J Neurol doi: 10.1111/j.1468-1331.2005.00936.x – volume: 121 start-page: 154 year: 2010 ident: ref17 article-title: Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis publication-title: Acta Neurol Scand doi: 10.1111/j.1600-0404.2009.01285.x – volume: 38 start-page: 429 year: 2011 ident: ref25 article-title: Adherence to multiple sclerosis disease-modifying therapies in Ontario is low publication-title: Can J Neurol Sci doi: 10.1017/S0317167100011823 – volume: 58 start-page: 840 year: 2005 ident: ref12 article-title: Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria" publication-title: Ann Neurol doi: 10.1002/ana.20703 – volume: 30 start-page: 148 year: 2009 ident: ref35 article-title: Adherence and persistence with omalizumab and fluticasone/salmeterol within a managed care population publication-title: Allergy Asthma Proc doi: 10.2500/aap.2009.30.3190 – volume: 114 start-page: 1145 year: 2012 ident: ref29 article-title: Long-term adherence to interferon-beta treatment in a cohort of RRMS patients in Belgrade, Serbia publication-title: Clin Neurol Neurosurg doi: 10.1016/j.clineuro.2012.02.043 – volume: 4 start-page: 1 year: 2010 ident: ref8 article-title: Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence publication-title: Patient Prefer Adherence doi: 10.2147/PPA.S8230 – volume: 14 start-page: 11 year: 2014 ident: ref27 article-title: Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001–2010 publication-title: BMC Neurol doi: 10.1186/1471-2377-14-11 – volume: 66 start-page: 2171 year: 2009 ident: ref38 article-title: Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin publication-title: Am J Health Syst Pharm doi: 10.2146/ajhp080711 – volume: 37 start-page: 173 year: 2012 ident: ref36 article-title: Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease publication-title: J Clin Pharm Ther doi: 10.1111/j.1365-2710.2011.01276.x – volume: 43 start-page: 655 year: 1993 ident: ref2 article-title: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group publication-title: Neurology doi: 10.1212/WNL.43.4.655 – volume: 56 start-page: 422 year: 2001 ident: ref19 article-title: Enhancement frequency decreases with increasing age in relapsing-remitting multiple sclerosis publication-title: Neurology doi: 10.1212/WNL.56.3.422 – volume: 13 start-page: 633 year: 2010 ident: ref11 article-title: Medication adherence with disease modifying treatments for multiple sclerosis among US employees publication-title: J Med Econ doi: 10.3111/13696998.2010.527588 – volume: 23 start-page: 1154 year: 2011 ident: ref24 article-title: A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States publication-title: AIDS Care doi: 10.1080/09540121.2010.543884 – volume: 33 start-page: 219 year: 2010 ident: ref9 article-title: Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition publication-title: J Behav Med doi: 10.1007/s10865-010-9247-y – volume: 39 start-page: 285 year: 1996 ident: ref4 article-title: Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) publication-title: Ann Neurol doi: 10.1002/ana.410390304 – volume: 16 start-page: 116 year: 2010 ident: ref23 article-title: Pattern of statin use among 10 cohorts of new users from 1995 to 2004: a register-based nationwide study publication-title: Am J Manag Care – volume: 5 start-page: 73 year: 2011 ident: ref14 article-title: Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis publication-title: Patient Prefer Adherence doi: 10.2147/PPA.S15702 – volume: 32 start-page: 108 year: 2010 ident: ref33 article-title: Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands publication-title: Clin Ther doi: 10.1016/j.clinthera.2010.01.008 – volume: 8 start-page: 647 year: 2012 ident: ref1 article-title: Progressive multiple sclerosis: pathology and pathogenesis publication-title: Nat Rev Neurol doi: 10.1038/nrneurol.2012.168 – volume: 11 start-page: 306 year: 2005 ident: ref18 article-title: Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis publication-title: Mult Scler doi: 10.1191/1352458505ms1173oa – volume: 8 start-page: e59694 year: 2013 ident: ref15 article-title: The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform publication-title: PLoS One doi: 10.1371/journal.pone.0059694 – volume: 59 start-page: 131 year: 2008 ident: ref22 article-title: Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis publication-title: Eur Neurol doi: 10.1159/000111875 – volume: 11 start-page: 122 year: 2011 ident: ref21 article-title: Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study publication-title: BMC Neurol doi: 10.1186/1471-2377-11-122 – volume: 6 start-page: 61 year: 2012 ident: ref34 article-title: One-year treatment continuation in patients prescribed risperidone long-acting injection in New Zealand: a retrospective study publication-title: Clin Schizophr Relat Psychoses doi: 10.3371/CSRP.6.2.3 – volume: 61 start-page: 551 year: 2003 ident: ref28 article-title: Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS publication-title: Neurology doi: 10.1212/01.WNL.0000078885.05053.7D – volume: 33 start-page: 251 year: 2008 ident: ref37 article-title: Persistence with hepatitis C therapy in the Department of Veterans Affairs publication-title: J Clin Pharm Ther doi: 10.1111/j.1365-2710.2008.00912.x – volume: 28 start-page: 1411 year: 2006 ident: ref6 article-title: Toward a standard definition and measurement of persistence with drug therapy: Examples from research on statin and antihypertensive utilization publication-title: Clin Ther doi: 10.1016/j.clinthera.2006.09.021 – volume: 11 start-page: 46 year: 2005 ident: ref10 article-title: Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns publication-title: Mult Scler doi: 10.1191/1352458505ms1131oa – year: 2003 ident: ref7 article-title: Adherence to long-term therapies: evidence for action – volume: 34 start-page: 341 year: 2012 ident: ref16 article-title: Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study publication-title: Clin Ther doi: 10.1016/j.clinthera.2012.01.006
SSID	ssj0053866
Score	2.3036513
Snippet	Disease modifying therapies (DMTs) reduce the frequency of relapses and accumulation of disability in multiple sclerosis (MS). Long-term persistence with...
SourceID	plos doaj pubmedcentral proquest gale pubmed crossref
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source
StartPage	e0123824
SubjectTerms	Adult Adults Analysis Autoimmune diseases Biological response modifiers Cohort analysis Cohort Studies Copolymer 1 Diabetes Drug dosages Female Footprints Glatiramer Acetate - administration & dosage Hepatitis Humans Injections, Subcutaneous Interferon Interferon beta-1a - administration & dosage Interferon beta-1b - administration & dosage Male Medicine Middle Aged Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - drug therapy Neurosciences Nurses Observational studies Patients Population Population studies Pregnancy Rank tests Regression analysis Regression models Switches β-Interferon
SummonAdditionalLinks	– databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Jb9UwELbQEwcuiLI1pYBBSMDBbRI7XrgVRAVSVRBL1VvkOHaJVJKnl_eQeuG343GcqEGVyoFrPNlmy3gy8w1CLzJqDa_qlAjHKWFMSwIoU4TV1lSVErULWHonR-L4WJ6eqs-XRn1BTdgADzwwbp86aaQTaeoKxTKtdKqsKrTykYXQtg7opalQ42Zq8MHeijmPjXJUZPtRLnvLrrV7EEXInM0-RAGvf_LKi-V5118Vcv5dOXnpU3R4B92OMSQ-GJ59C92w7V20Fa20x68ilPTre-j3UdeeEfC-eAmJsT5EyBiSr7hpIQUDnVN4aMK68Icw9LYsIX9AVvZnE4qi8Vh0iHt_O_8yTf8G6xZnklx4O8FdNWV2_VPBxN3VGgfY2vvo--H7b-8-kDhxgRiu8jWhmnNW67wWVV6nWirHdW51oZ1lzNaVU4VSWuY6rbiqTcqM044LK7SStrCUPkCL1vN4G2EvgUxnlFfScGZEWlHrCqGEYX7L5pRIEB3ZX5oIRw5TMc7L8I9N-G3JwM0ShFZGoSWITGctBziOa-jfgmQnWgDTDge8ipVRxcrrVCxBT0EvyqEzdXIJ5QHL8xQqBGmCngcKANRooWLnTG_6vvz46eQfiL5-mRG9jESu8-wwOnZJ-HcCoK4Z5e6M0rsFM1veBi0eudKXGRc0g1QX92eOmn318rNpGS4KVXit7TYDDUw1ylWCHg6GMHE2LyRAAXpmiZmJzFg_X2mbHwHP3MfEhb_xzv-Q1SN0y4e0Bfzvy-guWqxXG_sY3TS_1k2_ehKcxB82vm_G priority: 102 providerName: Directory of Open Access Journals – databaseName: Nursing & Allied Health Database dbid: 7RV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZgQYgL0PLoQgGDkKAHt0ns-MEFLRUVlfpA21KVU-Q4drtSSZbNLhIXfjuexBsIqgCJ6_rLJhnPTMbj8TcIvYipNTwvIiIcp4QxLQmwTBFWWJPnShSu4dI72RMHB_L0VH0ICbc6lFUufWLjqIvKQI58K-aCxrBS52-mXwh0jYLd1dBC4yq6FkNs7PVZjE-WntjbMufhuBwV8VaYnc1pVdpNiCVkwnqfo4a1v_PNg-lFVV8WeP5eP_nLB2nn9v--yh10K4SieNTqzgq6YstVdGM_bLavopVg9zV-FcipN-6i73tVeUaOvT_HUDwPSuIhGNK5eLeEpA6cxcLHLVkBnpQYyu2mkJEgY_t50pRZ4_1QxoiP_J29YCb1azwqcSzJJ295-DDvcsX-Aberc79GwFDx-O0e-rjz7nj7PQk9HIjhKpkTqjlnhU4KkSdFpKVyXCdWp9pZxmyRO5UqpWWio5yrwkTMOO24sEIraVNL6X00KP18rSHsZzPWMeW5NJwZEeXUulQoYZhfBDolhogupzIzgeAc-mxcZM2unfALnVawGShAFhRgiEh31bQl-PgL_i1oSYcFeu7mh2p2lgVrz6iTRjoRRS5VLNZKR8qqVCsfDgtti3SInoKOZe1Z187JZCOWeL3gTNIhet4ggKKjhBqgM72o62z38OQfQEfjHuhlALnKi8PocO7CvxNQf_WQ6z2kdzSmN7wGFrGUSp391GN_5VLTLx9-1g3Dn0JdX2mrRYuBPkmJGqIHrVF1kk1SCeSCXliiZ2490fdHysl5w5Duo-zU3_jhnx_rEbrpw98U9gZjuo4G89nCPkbXzdf5pJ49aVzJD1Hff58 priority: 102 providerName: ProQuest
Title	Long-Term Persistence with Injectable Therapy in Relapsing-Remitting Multiple Sclerosis: An 18-Year Observational Cohort Study
URI	https://www.ncbi.nlm.nih.gov/pubmed/25867095 https://www.proquest.com/docview/1673120276 https://www.proquest.com/docview/1673372029 https://pubmed.ncbi.nlm.nih.gov/PMC4395027 https://doaj.org/article/3f8c8f700f5941a9a09e95a96507aed5 http://dx.doi.org/10.1371/journal.pone.0123824
Volume	10
WOSCitedRecordID	wos000352845100215&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: Directory of Open Access Journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Advanced Technologies & Aerospace Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: P5Z dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/hightechjournals providerName: ProQuest – providerCode: PRVPQU databaseName: Agriculture Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M0K dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/agriculturejournals providerName: ProQuest – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7P dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Engineering Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7S dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com providerName: ProQuest – providerCode: PRVPQU databaseName: Environmental Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PATMY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/environmentalscience providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7X7 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Materials Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: KB. dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/materialsscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7RV dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: BENPR dateStart: 20061201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PIMPY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 8C1 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVATS databaseName: Public Library of Science (PLoS) Journals Open Access customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: FPL dateStart: 20060101 isFulltext: true titleUrlDefault: http://www.plos.org/publications/ providerName: Public Library of Science
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dT9RAEN8IGOOLCn5wiudqTNSHYttt98M3IBAJHDQHEvCl2W534RLsXeidiS_-7c60vWoJRH2Zh9vZ63Z2ZzozO_tbQt4GzBqe5b4nHGdeFGnpIcqUF-XWZJkSuauw9E72xcGBPD1Vye9A8doOPhPBx0am65NxYdfRA5BhtECWQsY5Bls7yf7c8oLuct4cj7utZ-fzU6H0t7Z4cXI5Lm9yNK_XS_7xAdp5-L9Df0QeNK4m3ajXxjK5Y4sVcm_QbKavkOVGr0v6vgGf_vCY_NwfF-feMdhrisXxuAiAhWK6lu4WmLTBs1b0uAYjoKOCYjndBDMO3tB-G1Vl1HTQlCnSI3gyCGJUfqIbBQ2kdwaaRQ-zNhcMA9waX0AMQLGi8ccT8mVn-3jrs9fc0eAZrsKpxzTnUa7DXGRh7mupHNeh1bF2NopsnjkVK6VlqP2Mq9z4kXHacWGFVtLGlrGnZLEA8awSCrMX6IDxTBoeGeFnzLpYKGEiCPKcEj3C5lOXmgbAHO_RuEyrXTkBgUwt2BTlnTby7hGv7TWpATz-wr-Jq6LlRfjt6geY2LTR5pQ5aaQTvu9iFQVaaV9ZFWsF7q7QNo975BWuqbQ-y9oakXQjCkMfawpZj7ypOBCCo8Aan3M9K8t09_DkH5iOhh2mdw2TG4M4jG7OVcA7IbRXh3OtwwmGxHSaV1ED5lIp04ALFmByjEPPuVbc3Py6bcY_xbq9wo5nNQ_egxSqHnlWK1Er2TCWCB4IwhId9eqIvttSjC4qBHTwomN48PPbR_yC3AfXNsZ9v4CtkcXp1cy-JHfN9-movOqTBTE8QXoqKiqByq2gT5Y2tw-SYb_KzPQr4wJ0b3Md6MDfQyqSih4BTeKv0CPZHSRnvwATw3pj
linkProvider	Public Library of Science
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwELemgYAXYONjhcEMAjEesuXDsWMkhMpgWrW2m7YyDV6C49hdpZGUpQPthT-JvxFf4gSCJuBlD7zWlya53J3vzne_Q-iJFyhJk9R1mKaBQ4iIHECZckiqZJJwluoSS--gz4bD6PCQ786h73UvDJRV1jaxNNRpLiFHvu5RFngQqdNX088OTI2C09V6hEYlFtvq7KsJ2YqXvTfm-z71_c23o40tx04VcCTl_swJBKUkFX7KEj91RcQ1Fb4SodCKEJUmmoeci8gXbkJ5Kl0itdCUKSZ4pEIFCVBj8i8R4rugRbvhh9ryG9tBqW3PC5i3bqVhbZpnag18l8gnre2vnBLQ7AXz0-O8OM_R_b1e85cNcPPG_8a6m-i6dbVxt9KNBTSnskV0ZWCLCRbRgrVrBV614NvPb6Fv_TwbOyOzX2FoDgAlMCQY0tW4l0HSCnrN8KgCY8CTDEM54RQyLs6e-jQpy8jxwJZp4n1zZ_MhJsUL3M2wFznvDR_wTtLkws0DbuRHJgbCUNF5dhu9uxCW3EHzmZGPJYSN9HjCC2gSSUokc5NA6ZBxJokJcjVnHRTUohNLC-AOc0SO4_JUkplArmJsDAIXW4HrIKe5aloBmPyF_jVIZUML8OPlD_nJOLbWLA50JCPNXFeHnHiCC5crHgpu3H0mVBp20ArIdFz18jZGNO4S38ghJVHQQY9LCoAgyaDGaSxOiyLu7Rz8A9H-XovomSXSuWGHFLavxLwTQJu1KJdblMaQytbyEmhgzZUi_qk35spas85fftQsw59C3WKm8tOKBuZA-byD7lZK3HDWDyMATzTMYi31brG-vZJNjkoEeBNFhObG9_78WCvo6tZo0I_7veH2fXTNuPohnIN6wTKan52cqgfosvwymxQnD0szhtHHi1b-H_HZ4GE
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bT9VAEN4QNMYXFbxwFGU1GvWh0Mt2t2tiDILEE64BJOhL3W534STYHiloePGH-eucabfVGqK-8ODr2elpO_1mZmd2LoQ8DiKjeZb7nrA88hhTiYddpjyWG51lUuS27qW3tyY2NpL9fbk1Qb63tTCYVtnqxFpR56XGGPlCwEUUoKfOF6xLi9haXnk1_uzhBCk8aW3HaTQQWTVnX8F9q14Ol-FbPwnDlTe7S289N2HA01yGJ16kOGe5CnORhbmvEmm5Co2KlTWMmTyzMpZSJaHyMy5z7TNtleXCCCUTExsMhoL6vyTAx8R0wq34Q2sFQI9w7kr1IhEsOGTMj8vCzOM-JglZzxTWEwM6uzA5Piqr8za9v-du_mIMV67_z2y8Qa65LThdbGRmikyYYppcWXdJBtNkyum7ij5zTbmf3yTf1sriwNsFO0axaACFA0gohrHpsMBgFtag0d2mSQMdFRTTDMcYifG2zadRnV5O1136Jt2BO8NHGVUv6GJBg8R7D3ygm1kXI4cHXCoPwTeimOl5dou8uxCW3CaTBWBlhlBAUqCCiGeJ5kwLP4uMjYUUmoHza6UYkKiFUapdY3ecL3KU1qeVAhy8hrEpgi914BsQr7tq3DQ2-Qv9a0RoR4ttyesfyuOD1Gm5NLKJTqzwfRtLFiipfGlkrCS4AUKZPB6QOcR32tT4dso1XWQhYJKzJBqQRzUFtiYpEJ0H6rSq0uHm3j8Q7Wz3iJ46IlsCO7Ry9SbwTtjyrEc526MEBat7yzMojS1XqvSnDMGVrZSdv_ywW8Y_xXzGwpSnDQ3OhwrlgNxpBLrjbBgn2FQRmCV6ot5jfX-lGB3WneHBu4jhxnf__Fhz5ArIfLo23Fi9R66CBxDj8WgQzZLJk-NTc59c1l9ORtXxg1qjUfLxomX_BxkC6Ss
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long-Term+Persistence+with+Injectable+Therapy+in+Relapsing-Remitting+Multiple+Sclerosis%3A+An+18-Year+Observational+Cohort+Study&rft.jtitle=PloS+one&rft.au=Zhornitsky%2C+Simon&rft.au=Greenfield%2C+Jamie&rft.au=Koch%2C+Marcus+W.&rft.au=Patten%2C+Scott+B.&rft.date=2015-04-13&rft.pub=Public+Library+of+Science&rft.eissn=1932-6203&rft.volume=10&rft.issue=4&rft_id=info:doi/10.1371%2Fjournal.pone.0123824&rft_id=info%3Apmid%2F25867095&rft.externalDocID=PMC4395027
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon